Table 2 Clinicopathologic characteristics and immunohistochemical expression of NKX2.5 of the PTC tumor (N = 51). Data were analyzed by Fisher’s exact test
From: NKX2.5 is expressed in papillary thyroid carcinomas and regulates differentiation in thyroid cells
Variable | Category | Score of NKX2.5 | |||
Negative No. (%) | Low No. (%) | High No. (%) | p Value | ||
NKX2.5 expression | Negative | 24 (47.1%) | 0 (0.0%) | 0 (0.0%) | |
Positive | 0 (0.0%) | 16 (31.4%) | 11 (21.6%) | ||
Outcome | Without recurrence or persistence | 7 (13.7%) | 6 (11.8%) | 8 (15.7%) | 0.013 |
Recurrence | 3 (5.9%) | 6 (11.8%) | 0 (0.0%) | ||
Persistence | 14 (27.5%) | 4 (7.8%) | 3 (5.9%) | ||
Pathological stage of primary tumor size (pT) | pT1 and pT2 | 14 (27.5%) | 3 (5.9%) | 6 (11.8%) | 0.029 |
pT3 and pT4 | 10 (19.6%) | 13 (25.5%) | 4 (7.8%) | ||
pTx | 0 (0.0%) | 0 (0.0%) | 1 (2.0%) | ||